Inborn Errors of Metabolism of Amino Acids or Other Organic Acids: Complete ICD-11 Coding Guide

1. Introduction

Inborn errors of amino acid metabolism or other organic acids represent a heterogeneous group of rare genetic diseases that affect metabolic pathways essential for protein processing and organic compound metabolism. These conditions result from hereditary enzymatic deficiencies that prevent adequate degradation of specific amino acids or metabolism of organic acids, leading to accumulation of toxic metabolites in the body.

The clinical importance of these disorders is significant, as many can cause irreversible neurological damage, developmental impairment, acute metabolic crises, and in untreated cases, death. Classic examples include phenylketonuria, maple syrup urine disease, organic acidurias such as methylmalonic and propionic acidemia, homocystinuria, tyrosinemia, among others.

From a public health perspective, these disorders justify newborn screening programs in various countries, allowing early diagnosis and intervention before irreversible damage occurs. Early diagnosis, often through expanded newborn screening (heel prick test), is crucial for initiating appropriate dietary and pharmacological treatment.

Correct coding of these disorders is critical for multiple reasons: it facilitates epidemiological tracking of rare diseases, allows adequate allocation of resources for specialized treatments, aids in clinical research and development of new therapies, and ensures appropriate documentation for longitudinal follow-up of these patients who require multidisciplinary care throughout their lives.

2. Correct ICD-11 Code

Code: 5C50

Description: Inborn errors of metabolism of amino acids or other organic acids

Parent category: Hereditary metabolic diseases

This code in ICD-11 functions as a comprehensive category that encompasses various specific disorders of amino acid and organic acid metabolism. The ICD-11 structure allows greater specificity through subcategories, providing more precise coding when the specific diagnosis is established.

Code 5C50 represents an important evolution in the classification of these disorders, grouping conditions that share similar pathophysiological mechanisms - hereditary enzymatic deficiencies that affect metabolic pathways of amino acids and organic acids. This categorization facilitates the recognition of common clinical patterns, such as episodes of metabolic decompensation, metabolic acidosis, hyperammonemia, and progressive neurological manifestations.

The hierarchical structure of ICD-11 allows professionals to use this code when the specific diagnosis has not yet been completely established, but there is clinical and laboratory evidence of an inborn error of metabolism in this category, facilitating the diagnostic process and ensuring adequate documentation from the initial phases of investigation.

3. When to Use This Code

Code 5C50 should be used in specific clinical situations where there is confirmation or strong suspicion of inborn error of amino acid or organic acid metabolism. Below are detailed practical scenarios:

Scenario 1: Neonate with Positive Newborn Screening

Seven-day-old newborn with abnormal results on expanded newborn screening showing elevated serum phenylalanine levels, with values suggestive of phenylketonuria. The patient is asymptomatic but requires diagnostic confirmation with quantitative serum dosages and genetic investigation. In this case, code 5C50 is appropriate until definitive diagnostic confirmation, when it can then be specified to the corresponding subcategory.

Scenario 2: Infant with Acute Metabolic Crisis

Three-month-old infant previously healthy who presents with recurrent vomiting, progressive lethargy, and feeding refusal following an infectious illness. Laboratory tests reveal metabolic acidosis with increased anion gap, significant ketonuria, and hyperammonemia. Investigation with amino acid and organic acid urine profile is ongoing. Code 5C50 is appropriate for documenting clinical suspicion while awaiting specific laboratory confirmation.

Scenario 3: Child with Developmental Delay and Metabolic Findings

Eighteen-month-old child with global psychomotor developmental delay, hypotonia, difficult-to-control seizures, and characteristic body odor. Metabolic investigation reveals elevated branched-chain amino acid pattern, suggestive of maple syrup urine disease. Code 5C50 appropriately documents this specific inborn error.

Scenario 4: Patient with Progressive Neurological Manifestations

Adolescent with history of recurrent episodes of mental confusion, especially after high protein intake, with episodes of ataxia and behavioral changes. Investigation reveals homocystinuria with elevated plasma homocysteine and methionine levels. Code 5C50 is appropriate for this specific condition of amino acid metabolism.

Scenario 5: Presymptomatic Diagnosis Due to Family History

Newborn sibling of patient with confirmed methylmalonic acidemia, submitted to early metabolic investigation that confirms elevated methylmalonic acid and propionylcarnitine. Even though asymptomatic, the diagnosis confirms inborn error of organic acid metabolism, justifying code 5C50.

Scenario 6: Patient with Chronic Systemic Complications

Young adult patient with established diagnosis of tyrosinemia type I, presenting with chronic hepatic dysfunction, renal tubulopathy, and peripheral neuropathy secondary to the metabolic error. Code 5C50 documents the underlying condition responsible for systemic manifestations.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 5C50 is not appropriate, avoiding diagnostic confusion and ensuring accurate coding:

Carbohydrate Metabolism Errors: Conditions such as galactosemia, hereditary fructose intolerance, glycogenoses, and gluconeogenesis defects should be coded with 5C51. Although they may present with overlapping clinical manifestations, the primary metabolic defect involves carbohydrates, not amino acids or organic acids.

Lipid Metabolism Errors: Lysosomal storage diseases (Gaucher disease, Niemann-Pick disease), leukodystrophies, fatty acid beta-oxidation defects, and hereditary dyslipidemias require code 5C52. Even though some beta-oxidation defects may present with organic acidosis, the primary defect is in lipid metabolism.

Mitochondrial Disorders and Energy Metabolism Disorders: Mitochondrial respiratory chain defects, oxidative phosphorylation defects, and other mitochondrial cytopathies should be coded with 5C53. Although they may present with lactic acidosis and secondary metabolic alterations, the primary defect affects energy production.

Acquired Nutritional Deficiencies: Hypoaminoacidemia or alterations in amino acid profile secondary to protein-caloric malnutrition, intestinal malabsorption, or acquired liver diseases should not use this code, as they do not represent inborn errors of metabolism.

Metabolic Acidosis of Other Etiologies: Lactic acidosis secondary to sepsis, shock, acute renal failure, or diabetic ketoacidosis are not inborn errors of metabolism and require appropriate coding for the underlying condition.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation of inborn errors of amino acid or organic acid metabolism requires a systematic approach. Initially, evaluate the clinical history seeking: family history of consanguinity, unexplained neonatal deaths, affected siblings, symptoms triggered by fasting or protein intake, recurrent metabolic decompensation crises.

Physical examination should identify suggestive signs such as characteristic body odor (maple syrup, sweaty feet), facial dysmorphisms, hepatosplenomegaly, neurological alterations (hypotonia, hypertonia, developmental delay, seizures), ophthalmological alterations (lens dislocation in homocystinuria), abnormal cutaneous or hair manifestations.

Essential laboratory investigations include: arterial blood gas (metabolic acidosis), serum ammonia dosage (hyperammonemia), blood glucose (hypoglycemia in some disorders), liver and kidney function. Fundamental specialized tests are: quantitative plasma amino acid profile, urinary organic acid profile, acylcarnitine profile, and molecular genetic testing when available.

Step 2: Verify Specifiers

Once the diagnosis of inborn error of metabolism is established, determine the specificity: identify which amino acid or organic acid is involved (phenylalanine, leucine/isoleucine/valine, methionine, tyrosine, methylmalonic acid, propionic acid, etc.).

Assess clinical severity: severe neonatal form with acute decompensation, late-onset form with chronic manifestations, or mild form identified only on screening. Document present complications: neurological impairment (degree of developmental delay, presence of seizures), organ dysfunction (hepatopathy, nephropathy, cardiomyopathy), previous metabolic crises.

Classify regarding therapeutic responsiveness when applicable: responsiveness to vitamins (B6 in homocystinuria, B12 in methylmalonic acidemia), control with dietary restriction, need for special formulas or supplementation.

Step 3: Differentiate from Other Codes

5C51 - Inborn errors of carbohydrate metabolism: The key difference lies in the affected metabolic substrate. While 5C50 involves defects in amino acid metabolism (protein components) or organic acids derived from intermediate metabolism, 5C51 specifically affects carbohydrates such as galactose, fructose, or glycogen. Clinically, carbohydrate errors frequently present hypoglycemia as a prominent manifestation, while amino acid errors more commonly present with hyperammonemia and organic acidosis.

5C52 - Inborn errors of lipid metabolism: The fundamental distinction lies in the type of molecule affected. Code 5C52 encompasses defects in the metabolism of fatty acids, cholesterol, sphingolipids, and phospholipids. Manifestations such as hepatomegaly from lipid deposition, rhabdomyolysis, hypoketotic hypoglycemia (in beta-oxidation defects), and progressive demyelination are more characteristic of lipid errors than of aminoacidopathies.

5C53 - Inborn errors of energy metabolism: This code applies to defects in cellular energy production, mainly mitochondrial respiratory chain disorders. The main difference is that 5C53 involves defects in oxidative phosphorylation and ATP production, manifesting with myopathy, persistent lactic acidosis, progressive multi-systemic involvement, and evidence of mitochondrial dysfunction on muscle biopsy, while 5C50 involves specific enzymatic defects in amino acid catabolic pathways.

Step 4: Required Documentation

Adequate documentation should include complete checklist: detailed description of clinical presentation (age of onset, initial symptoms, triggering factors), neonatal screening results when applicable, results of general laboratory tests (blood gas, ammonia, blood glucose, lactate), results of specialized metabolic tests (amino acid profile with quantitative values, urinary organic acid profile, acylcarnitine profile).

Record diagnostic confirmation: method used (biochemical, enzymatic, genetic), responsible laboratory, interpretation of findings. Document family history: pedigree when relevant, consanguinity, known family cases, carrier screening when performed.

Include established therapeutic plan: specific dietary restrictions, prescribed special formulas, vitamin supplementation, specific medications, emergency protocol for metabolic crises. Document treatment response: metabolic control (normalization or improvement of laboratory parameters), evolution of neuropsychomotor development, occurrence of decompensations.

6. Complete Practical Example

Clinical Case

A 4-month-old male infant is brought to the emergency department with a 3-day history of vomiting, progressive feeding refusal, and excessive drowsiness. The mother reports that the child was doing well until presenting with a cold 5 days ago, when he started decreasing food intake.

Past medical history reveals that the child was born via vaginal delivery, at term, with adequate birth weight. Basic neonatal screening was normal. Neuropsychomotor development had been considered adequate until the current episode. Family history reveals that the parents are second-degree cousins, and there was a previous sibling who died at 6 months of age with a similar presentation, without an established diagnosis.

On physical examination, the patient appears dehydrated (++/4+), lethargic, hypotonic, with normotensive anterior fontanelle. Cardiopulmonary auscultation without abnormalities. Abdomen without hepatosplenomegaly. The mother reports a characteristic sweet-smelling odor in the urine.

Initial laboratory tests: arterial blood gas showing pH 7.18, HCO3 12 mEq/L, pCO2 28 mmHg (metabolic acidosis with partial respiratory compensation), anion gap of 24 (elevated). Blood glucose 65 mg/dL. Serum ammonia 180 μmol/L (elevated, normal up to 80). Renal function preserved. Complete blood count without significant abnormalities. Ketonuria 3+.

Given the clinical presentation suggestive of inborn error of metabolism, the following were requested: plasma amino acid profile and urinary organic acid profile. The patient was admitted to the intensive care unit, receiving vigorous intravenous hydration with glucose solution, temporary suspension of dietary proteins, and rigorous monitoring.

Results of specialized metabolic tests returned in 48 hours revealing marked elevation of leucine, isoleucine, and valine in plasma, with presence of alloisoleucine. Urinary organic acid profile showed elevation of branched-chain ketoacids. The clinical and laboratory presentation confirmed the diagnosis of maple syrup urine disease (branched-chain ketoaciduria).

Coding Step by Step

Criteria Analysis:

The patient presents all criteria for inborn error of amino acid metabolism: compatible clinical manifestation (acute metabolic decompensation triggered by catabolism during infection), characteristic laboratory findings (metabolic acidosis, mild hyperammonemia, ketonuria), biochemical confirmation (elevation of branched-chain amino acids), suggestive family history (consanguinity, sibling who died with similar presentation).

Code Selected: 5C50

This code is appropriate because maple syrup urine disease is an inborn error of branched-chain amino acid metabolism (leucine, isoleucine, valine), caused by deficiency of the branched-chain ketoacid dehydrogenase enzyme complex. The condition fits perfectly within category 5C50.

Complete Justification:

The coding with 5C50 is justified by the following points: (1) Biochemical confirmation of specific aminoacidopathy through quantitative amino acid profile; (2) Typical clinical manifestations of inborn error of metabolism with acute decompensation; (3) Exclusion of other metabolic categories - it is not a carbohydrate disorder (blood glucose relatively preserved, without significant hypoglycemia), it is not a lipid disorder (absence of hepatomegaly, rhabdomyolysis, or hypoketotic hypoglycemia), it is not a primary energy defect (absence of lactic acidosis, mitochondrial manifestations); (4) Autosomal recessive inheritance pattern evident from parental consanguinity.

Complementary Codes:

In addition to the main code 5C50, codes may be added to document complications and manifestations: code for metabolic acidosis (manifestation of decompensation), code for neuropsychomotor developmental delay if present after resolution of the acute episode, code for respiratory infection (triggering factor of the metabolic crisis).

7. Related Codes and Differentiation

Within the Same Category

5C51: Inborn errors of carbohydrate metabolism

When to use vs. 5C50: Use 5C51 when the primary metabolic defect involves carbohydrate processing. Examples include galactosemia (defect in galactose metabolism), hereditary fructose intolerance (defect in fructose metabolism), glycogenoses (defects in glycogen storage or mobilization).

Main difference: While 5C50 affects pathways of protein degradation and their constituent amino acids or organic acids of intermediate metabolism, 5C51 specifically affects pathways of sugar metabolism. Clinically, carbohydrate errors frequently present with hypoglycemia as a central manifestation, hepatomegaly from glycogen accumulation, and symptoms triggered by specific carbohydrate intake, unlike aminoacidopathies which present with hyperammonemia and symptoms related to protein intake.

5C52: Inborn errors of lipid metabolism

When to use vs. 5C50: Code 5C52 is appropriate when the defect involves fat metabolism, including defects of beta-oxidation of fatty acids, lysosomal lipid storage diseases, defects in cholesterol synthesis or degradation, leukodystrophies, and sphingolipidoses.

Main difference: Lipid errors typically manifest with hepatomegaly from fatty infiltration or sphingolipid deposition, hypoketotic hypoglycemia (in beta-oxidation defects), rhabdomyolysis, cardiomyopathy, progressive demyelination of the central nervous system. Laboratory findings show altered acylcarnitine profile (in beta-oxidation defects) or evidence of lysosomal accumulation, unlike aminoacidopathies which present with alterations in amino acid and organic acid profiles.

5C53: Inborn errors of energy metabolism

When to use vs. 5C50: Use 5C53 for defects of the mitochondrial respiratory chain, defects of oxidative phosphorylation, defects of pyruvate metabolism, and other mitochondrial cytopathies that primarily affect cellular energy production.

Main difference: Energy metabolism disorders present with persistent lactic acidosis (not only during decompensations), elevated lactate/pyruvate ratio, progressive multi-systemic involvement affecting tissues with high energy demand (brain, muscle, heart), histological evidence of mitochondrial dysfunction (ragged red fibers on muscle biopsy), and demonstrable defects in respiratory chain complex activity. Aminoacidopathies do not present these specific mitochondrial characteristics.

Differential Diagnoses

Acquired Metabolic Encephalopathies: Conditions such as hepatic encephalopathy from cirrhosis, renal insufficiency with uremia, or severe electrolyte disturbances can mimic inborn errors of metabolism. They are distinguished by the presence of underlying liver or kidney disease, absence of specific alterations in amino acid or organic acid profiles, and resolution with treatment of the underlying condition.

Intoxications and Poisonings: Some intoxications can cause metabolic acidosis and neurological alterations similar to inborn errors. Differentiation is based on history of exposure, absence of characteristic pattern on specialized metabolic tests, and different temporal evolution.

Central Nervous System Infections: Meningitis and encephalitis can present with lethargy, vomiting, and neurological alterations. They differ by the presence of high fever, meningeal signs, cerebrospinal fluid pleocytosis, and absence of specific metabolic alterations.

8. Differences with ICD-10

In ICD-10, inborn errors of amino acid metabolism were coded primarily under E70 (Disorders of aromatic amino acid metabolism, including phenylketonuria, tyrosinemia, albinism), E71 (Disorders of branched-chain amino acid metabolism and fatty acid metabolism), and E72 (Other disorders of amino acid metabolism).

Organic acidurias were dispersed across different subcategories of E71, creating some fragmentation in the classification. ICD-10 rigidly separated aminoacidopathies from organic acidurias, although pathophysiologically these conditions are closely related.

The main change in ICD-11 with code 5C50 is conceptual unification, grouping errors of amino acid and organic acid metabolism under the same higher category, recognizing that many organic acidurias result directly from defective amino acid metabolism. This hierarchical structure facilitates coding and allows greater specificity through subcategories.

The practical impact of these changes includes: simplification of the coding process by reducing ambiguities about which E7X code to use, improved epidemiological tracking by grouping related conditions, facilitation of research and multicenter studies that can now utilize more uniform categorization, and greater alignment with current pathophysiological understanding of these disorders.

Professionals familiar with ICD-10 should be aware that multiple E70-E72 codes now converge to category 5C50, although specific subcategories still allow diagnostic detail when necessary.

9. Frequently Asked Questions

How is the diagnosis of inborn errors of amino acid or organic acid metabolism made?

Diagnosis generally begins with expanded newborn screening, which uses tandem mass spectrometry to detect elevations of amino acids and acylcarnitines in dried blood spot samples. When screening is positive or there is clinical suspicion, diagnostic confirmation is performed with quantitative tests: plasma amino acid profile by liquid chromatography or mass spectrometry, urinary organic acid profile by gas chromatography coupled to mass spectrometry, and acylcarnitine profile. Molecular genetic tests confirm specific mutations in the genes of affected enzymes. In some cases, enzyme activity assay in leukocytes or cultured fibroblasts may be necessary.

Is treatment available in public health systems?

Treatment availability varies considerably among different countries and health systems. Many public systems provide special formulas free or with low content of specific amino acids, essential for dietary management. Vitamin supplementation (such as vitamin B6, B12, biotin) when indicated is generally available. Specific medications such as nitisinone for tyrosinemia or betaine for homocystinuria may have variable availability. Multidisciplinary follow-up with geneticists, specialized nutritionists, and other professionals is a fundamental component, although access to specialized centers may be limited in some regions. Families should seek information from medical genetics services about resources available locally.

How long does treatment last?

Most inborn errors of amino acid or organic acid metabolism require lifelong treatment. Dietary restriction of specific amino acids, use of special formulas, and supplementation must be maintained continuously to prevent accumulation of toxic metabolites. Interruptions in treatment, even temporary ones, can result in acute metabolic decompensations or progressive neurological damage. The rigor of dietary control may vary with age: infants and children in rapid growth phases require more frequent monitoring and regular adjustments, while adults may have more stable needs, but equally require treatment maintenance. Regular medical follow-up with periodic amino acid dosing is essential to adjust therapy throughout life.

Can this code be used in medical certificates?

Yes, code 5C50 can and should be used in official medical documentation, including certificates, when appropriate. For certificates that justify absence from activities due to acute metabolic decompensations or procedures related to treatment, the code adequately documents the underlying condition. In some contexts, it may be preferable to use more specific subcategories when the precise diagnosis is known, providing more detailed documentation. For purposes of social benefits, documentation of disability, or special educational needs, appropriate coding is fundamental to ensure access to necessary resources and adaptations.

What are the warning signs of metabolic decompensation?

Family members and caregivers should be alert to signs indicating impending metabolic decompensation: persistent or recurrent vomiting, significant food refusal, lethargy or excessive drowsiness, unexplained irritability, alterations in level of consciousness, seizures, abnormal movements, altered body or urinary odor (sweet-smelling, sweaty feet, or other characteristic odors), rapid or labored breathing (may indicate acidosis), fever associated with disproportionate prostration. Intercurrent infections, prolonged fasting, excessive protein intake, vomiting from any cause, or surgical stress are risk situations. In the presence of these signs, seeking urgent medical care is essential, as early intervention prevents progression to metabolic coma and irreversible neurological damage.

Can women with these disorders have safe pregnancies?

Women with inborn errors of amino acid or organic acid metabolism can become pregnant, but require specialized preconception and prenatal follow-up. Strict metabolic control before conception and throughout pregnancy is crucial, as elevated levels of certain amino acids (especially phenylalanine) can cause fetal malformations and compromise the baby's neurological development. Maternal phenylketonuria, for example, requires strict phenylalanine control before and during pregnancy to prevent maternal phenylketonuria syndrome (microcephaly, heart disease, mental retardation in the fetus). Joint follow-up with high-risk obstetrics and a geneticist is essential. Genetic counseling should be offered to discuss risks of transmitting the condition to offspring.

What is the long-term follow-up of these patients like?

Longitudinal follow-up requires a multidisciplinary team including a geneticist or metabolist, nutritionist specialized in inborn errors of metabolism, neurologist, and other specialists as needed (hepatologist, nephrologist, ophthalmologist). Regular consultations are necessary for: periodic laboratory monitoring (amino acid profile, liver and kidney function, nutritional parameters), adjustment of dietary restrictions according to growth and individual needs, evaluation of neuropsychomotor and cognitive development, screening for complications specific to each disease (liver disease, kidney disease, osteoporosis, visual problems), guidance on management of intercurrent conditions and emergency situations. The frequency of consultations varies: infants may require monthly evaluations, older children quarterly or semiannually, adults with stable disease may have longer intervals, but always with maintenance of follow-up.

Is there a cure for these disorders?

Currently, most inborn errors of amino acid or organic acid metabolism do not have a definitive cure, but effective treatments allow disease control and prevention of complications. Management is based on reducing the accumulation of toxic metabolites through dietary restriction, use of special formulas, supplementation of vitamin cofactors when there is responsiveness, and specific medications. Emerging therapies include liver transplantation for selected cases (effective in some severe organic acidurias), enzyme replacement therapy in development for some conditions, and gene therapy in experimental phase. Early diagnosis through newborn screening and immediate initiation of treatment allow normal or near-normal development in many cases, demonstrating that adequate control can provide excellent quality of life even without definitive cure.

Keywords: ICD-11 5C50, inborn errors of metabolism, aminoacidopathies, organic acidurias, phenylketonuria, maple syrup urine disease, homocystinuria, methylmalonic acidemia, newborn screening, amino acid metabolism, medical coding, hereditary metabolic diseases.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Inborn Errors of Metabolism of Amino Acids or Other Organic Acids

Partager